Side-Effect Sensitivity Some patients have metabolic profiles that support GLP-1 therapy but struggle to tolerate standard starting doses
In the last decades, HFCS utilization has grown, essentially because of its longer shelf life, cheaper production, and higher sweetness which increases the palatability of sugary beverages, baked and processed foods [1, 2]
Improves overall glow and texture without needing expensive treatments
Several biological DMARDs have recently emerged including TNF-inhibitor (Amjevita, Renflexis, Erelzi, Cyltezo, Imradl), anti-CD20 antibody (Truxima, Rixathon), IL-6 receptor antibody (Kevzara), RANKL antibody (Pralia), and JAK inhibitor (Olumiant)